Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986165

Next Previous
Drug Profile

BMS 986165

Alternative Names: BMS-986165; BMS-986165-01

Latest Information Update: 07 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase II Crohn's disease; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis
  • Phase I Autoimmune disorders; Inflammatory bowel diseases; Liver disorders; Psoriasis

Most Recent Events

  • 30 Dec 2019 Bristol-Myers Squibb plans a phase I pharmacokinetic trial (In volunteers) in USA (PO,Tablet) (NCT04209699)
  • 08 Dec 2019 Bristol-Myers Squibb completes a phase I pharmacokinetic trial for Systemic lupus erythematosus (In volunteers) (PO) (NCT04065932)
  • 04 Dec 2019 Bristol-Myers Squibb completes a phase I trial for Healthy volunteers in USA (PO) (NCT04113668)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top